Relationship of minimal inhibitory concentration and bactericidal activity to efficacy of antibiotics for treatment of ventilator-associated pneumonia

被引:22
作者
Kiem, Sungmin
Schentag, Jerome J.
机构
[1] SUNY Buffalo, Sch Pharm, Buffalo, NY 14260 USA
[2] CPL Associates LLC, Amherst, NY USA
关键词
susceptibility of antibiotics; pharmacokinetics/pharmacodynamics of antibiotics; area under the inhibitory concentration-time curve; ventilator-associated pneumonia;
D O I
10.1055/s-2006-933674
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Although minimal inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) have been used as the most popular prediction tools for antimicrobial action, they have shortcomings. The MIC and MBC do not consider time-related antimicrobial effects, such as killing rate and postantibiotic effect. In this regard, the concept of pharmacokinetic and pharmacodynamic (PK/PD) modeling has been introduced to help interpret determinations of susceptibility breakpoints. Although area under the inhibitory concentration-time curve (AUIC) can be used as a universal PK/PD parameter, target magnitudes of the parameter have to be high enough to exert rapid bactericidal activity (> 250) and to prevent selection and induction of resistance (> 100). For vancomycin used in treatment of methicillin-resistant Staphylococcus aureus pneumonia, a much higher AUIC (400) is suggested to avoid treatment failure. For resistant gram-negative bacteria, such as Pseudomonas aeruginosa, the usual dosage of fourth-generation cephalosporins, carbapenems, and fluoroquinolones cannot achieve the target AUICs. Either combination therapy or higher dosage should be administered to achieve target AUICs and prevent the potential for failure. Unresolved issues, such as influence of protein binding, PK/PD at tissue sites versus blood, the impact of the immune system, should be addressed to refine the applicability of PK/PD in antibiotic treatment.
引用
收藏
页码:51 / 67
页数:17
相关论文
共 154 条
[41]   Validity of markers of dilution in small volume lung lavage [J].
Dargaville, PA ;
South, M ;
Vervaart, P ;
McDougall, PN .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1999, 160 (03) :778-784
[42]   From ecological reservoir to disease:: the nasopharynx, day-care centres and drug-resistant clones of Streptococcus pneumoniae [J].
de Lencastre, H ;
Tomasz, A .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 50 :75-81
[43]   Quinupristin-dalfopristin: An overview [J].
Delgado, G ;
Neuhauser, MM ;
Bearden, DT ;
Danziger, LH .
PHARMACOTHERAPY, 2000, 20 (12) :1469-1485
[44]   The mutant selection window and antimicrobial resistance [J].
Drlica, K .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 52 (01) :11-17
[45]   Prevention of resistance: A goal for dose selection for antimicrobial agents [J].
Drusano, GL .
CLINICAL INFECTIOUS DISEASES, 2003, 36 :S42-S50
[46]   Use of preclinical data for selection of a phase II/III dose for evernimicin and identification of a preclinical MIC breakpoint [J].
Drusano, GL ;
Preston, SL ;
Hardalo, C ;
Hare, R ;
Banfield, C ;
Andes, D ;
Vesga, O ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (01) :13-22
[47]   Pharmacodynamics in the study of drug resistance and establishing in vitro susceptibility breakpoints:: ready for prime time [J].
Dudley, MN ;
Ambrose, PG .
CURRENT OPINION IN MICROBIOLOGY, 2000, 3 (05) :515-521
[48]   Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia [J].
Dupont, H ;
Mentec, H ;
Sollet, JP ;
Bleichner, G .
INTENSIVE CARE MEDICINE, 2001, 27 (02) :355-362
[49]   Quinupristin-dalfopristin and linezolid: Evidence and opinion [J].
Eliopoulos, GM .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (04) :473-481
[50]   Should we reevaluate antibiotic breakpoints? [J].
Ferraro, MJ .
CLINICAL INFECTIOUS DISEASES, 2001, 33 :S227-S229